As shown in Figure 1, the mRNA expression of GXYLT2 was significantly increased in several common cancer datasets including head-neck squamous cell carcinoma (HNSC) and kidney renal clear carcinoma (KIRC), while significant downregulation of GXYLT2 was exposed in prostate adenocarcinoma (PRAD), uterine corpus endometrial carcinoma (UCEC), colon adenocarcinoma (COAD), and bladder urothelial carcinoma (BLCA)(Figures 1(a) and 1(b)). Here, GXYLT2 is linked to bladder transitional cell carcinoma.